DK3433369T3 - Rna-replikon til varieret og effektiv genekspression - Google Patents
Rna-replikon til varieret og effektiv genekspression Download PDFInfo
- Publication number
- DK3433369T3 DK3433369T3 DK17710528.5T DK17710528T DK3433369T3 DK 3433369 T3 DK3433369 T3 DK 3433369T3 DK 17710528 T DK17710528 T DK 17710528T DK 3433369 T3 DK3433369 T3 DK 3433369T3
- Authority
- DK
- Denmark
- Prior art keywords
- various
- gene expression
- rna replication
- effective gene
- effective
- Prior art date
Links
- 230000014509 gene expression Effects 0.000 title 1
- 230000010076 replication Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2016/056165 WO2017162266A1 (en) | 2016-03-21 | 2016-03-21 | Rna replicon for versatile and efficient gene expression |
| PCT/EP2017/055808 WO2017162460A1 (en) | 2016-03-21 | 2017-03-13 | Rna replicon for versatile and efficient gene expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3433369T3 true DK3433369T3 (da) | 2020-03-30 |
Family
ID=55587284
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17710528.5T DK3433369T3 (da) | 2016-03-21 | 2017-03-13 | Rna-replikon til varieret og effektiv genekspression |
| DK20156693.2T DK3701959T3 (da) | 2016-03-21 | 2017-03-13 | RNA-Replikon til alsidig og effektiv genekspression |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20156693.2T DK3701959T3 (da) | 2016-03-21 | 2017-03-13 | RNA-Replikon til alsidig og effektiv genekspression |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11168337B2 (da) |
| EP (2) | EP3701959B1 (da) |
| JP (2) | JP7121443B2 (da) |
| KR (1) | KR102161607B1 (da) |
| CN (2) | CN108884473B (da) |
| AU (1) | AU2017236239B2 (da) |
| CA (1) | CA3017272A1 (da) |
| CY (1) | CY1125086T1 (da) |
| DK (2) | DK3433369T3 (da) |
| ES (2) | ES2784711T3 (da) |
| HK (1) | HK1259449A1 (da) |
| HR (1) | HRP20220044T1 (da) |
| HU (2) | HUE050350T2 (da) |
| IL (2) | IL261379B (da) |
| LT (1) | LT3701959T (da) |
| MX (1) | MX2018011383A (da) |
| PL (2) | PL3433369T3 (da) |
| PT (2) | PT3701959T (da) |
| RS (1) | RS62864B1 (da) |
| RU (1) | RU2748892C2 (da) |
| SG (1) | SG11201807374WA (da) |
| SI (2) | SI3701959T1 (da) |
| SM (1) | SMT202200047T1 (da) |
| WO (2) | WO2017162266A1 (da) |
| ZA (1) | ZA201805519B (da) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201710973D0 (en) | 2017-07-07 | 2017-08-23 | Avacta Life Sciences Ltd | Scaffold proteins |
| CA3074919A1 (en) * | 2017-09-13 | 2019-03-21 | Biontech Cell & Gene Therapies Gmbh | Rna replicon for expressing a t cell receptor or an artificial t cell receptor |
| US20200277627A1 (en) * | 2017-09-13 | 2020-09-03 | Biontech Rna Pharmaceuticals Gmbh | Rna replicon for reprogramming somatic cells |
| WO2019137999A1 (en) | 2018-01-11 | 2019-07-18 | Biontech Rna Pharmaceuticals Gmbh | Formulation for administration of rna |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| JP2022536474A (ja) * | 2019-06-10 | 2022-08-17 | アクセス ツー アドバンスト ヘルス インスティチュート | アストロウイルスレプリコンの方法および組成物 |
| WO2021074695A1 (en) | 2019-10-16 | 2021-04-22 | Avacta Life Sciences Limited | PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES. |
| IL293051A (en) | 2019-11-18 | 2022-07-01 | Janssen Biotech Inc | Vaccines based on mutant calr and jak2 and their uses |
| CN110890127B (zh) * | 2019-11-27 | 2024-02-23 | 山东大学 | 酿酒酵母dna复制起始区域识别方法 |
| MX2022007905A (es) | 2019-12-31 | 2022-08-25 | Elixirgen Therapeutics Inc | Administracion transitoria basada en temperatura de acidos nucleicos y proteinas a celulas y tejidos. |
| EP4103228A1 (en) | 2020-02-13 | 2022-12-21 | Institut Pasteur | Nucleic acid vaccine against the sars-cov-2 coronavirus |
| EP4117725A4 (en) | 2020-03-09 | 2024-05-29 | Arcturus Therapeutics, Inc. | CORONAVIRUS VACCINE COMPOSITIONS AND METHODS |
| GB2594364A (en) * | 2020-04-22 | 2021-10-27 | Biontech Rna Pharmaceuticals Gmbh | Coronavirus vaccine |
| CN116096409A (zh) * | 2020-05-11 | 2023-05-09 | 杨森制药公司 | 编码稳定化的冠状病毒刺突蛋白的rna复制子 |
| EP4162034A1 (en) * | 2020-06-04 | 2023-04-12 | BioNTech SE | Rna replicon for versatile and efficient gene expression |
| GB202101299D0 (en) | 2020-06-09 | 2021-03-17 | Avacta Life Sciences Ltd | Diagnostic polypetides and methods |
| MX2023001853A (es) | 2020-08-14 | 2023-07-07 | Arcturus Therapeutics Inc | Método de liofilización de nanopartículas lípidicas. |
| WO2022198002A1 (en) * | 2021-03-19 | 2022-09-22 | Tiba Biotech Llc | Artificial alphavirus-derived rna replicon expression systems |
| KR20240006575A (ko) | 2021-04-26 | 2024-01-15 | 앵스띠뛰 파스퇴르 | SARS-CoV-2에 대한 사람 중화 모노클로날 항체 및 이의 용도 |
| WO2022234003A1 (en) | 2021-05-07 | 2022-11-10 | Avacta Life Sciences Limited | Cd33 binding polypeptides with stefin a protein |
| WO2023057946A1 (en) | 2021-10-07 | 2023-04-13 | Avacta Life Sciences Limited | Serum half-life extended pd-l1 binding polypeptides |
| WO2023057567A1 (en) | 2021-10-07 | 2023-04-13 | Avacta Life Sciences Limited | Pd-l1 binding affimers |
| AU2022372325A1 (en) | 2021-10-18 | 2024-05-02 | BioNTech SE | Methods for determining mutations for increasing modified replicable rna function and related compositions and their use |
| CA3234396A1 (en) | 2021-10-18 | 2023-04-27 | BioNTech SE | Modified replicable rna and related compositions and their use |
| EP4169578A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharide compounds and complexes |
| EP4286004A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Disulfide oligosaccharide compounds and complexes |
| EP4169580A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharide compounds and complexes |
| EP4169534A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharide complexes and uses |
| EP4286394A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide compounds and complexes |
| EP4286003A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide compounds and complexes |
| JP2024540979A (ja) | 2021-10-22 | 2024-11-06 | ビオンテック・ソシエタス・エウロパエア | オリゴ糖複合体及び用途 |
| US20250002522A1 (en) | 2021-10-22 | 2025-01-02 | BioNTech SE | Oligosaccharide compounds and complexes |
| EP4285933A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide complexes and uses |
| AU2022369405A1 (en) | 2021-10-22 | 2024-05-09 | BioNTech SE | Oligosaccharide compounds and complexes |
| WO2023067124A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Disulfide oligosaccharide compounds and complexes |
| JP2024543721A (ja) | 2021-10-22 | 2024-11-22 | ビオンテック・ソシエタス・エウロパエア | オリゴ糖複合体及び用途 |
| EP4186528A1 (en) | 2021-11-30 | 2023-05-31 | BioNTech SE | Oligosaccharide complexes and uses |
| EP4285932A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide complexes and uses |
| EP4169579A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Disulfide oligosaccharide compounds and complexes |
| CN119213021A (zh) | 2022-02-10 | 2024-12-27 | 艾菲赛尔治疗株式会社 | 与CD40L特异性结合的Stefin A蛋白变体及其用途 |
| CN114639442B (zh) * | 2022-03-30 | 2024-01-30 | 中国农业科学院农业基因组研究所 | 一种基于单核苷酸多态性预测开放阅读框的方法及系统 |
| WO2023213378A1 (en) | 2022-05-02 | 2023-11-09 | BioNTech SE | Replicon compositions and methods of using same for the treatment of diseases |
| WO2023218243A1 (en) | 2022-05-12 | 2023-11-16 | Avacta Life Sciences Limited | Lag-3/pd-l1 binding fusion proteins |
| WO2023232747A1 (en) | 2022-05-30 | 2023-12-07 | BioNTech SE | Complexes for delivery of nucleic acids |
| WO2024056856A1 (en) | 2022-09-15 | 2024-03-21 | BioNTech SE | Systems and compositions comprising trans-amplifying rna vectors with mirna |
| WO2024068674A1 (en) | 2022-09-26 | 2024-04-04 | BioNTech SE | Nucleic acid complexes and uses thereof |
| WO2024084462A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Nucleic acid complexes and uses thereof |
| WO2024176192A1 (en) | 2023-02-24 | 2024-08-29 | BioNTech SE | Immunogenic compositions |
| EP4442276A1 (en) | 2023-04-07 | 2024-10-09 | Institut Pasteur | Combined antibodies against sarbecoviruses and uses thereof |
| WO2024236192A1 (en) | 2023-05-17 | 2024-11-21 | Institut Pasteur | Heterodimer of poxvirus a16 and g9 proteins as an immunogen |
| WO2025026545A1 (en) | 2023-08-01 | 2025-02-06 | BioNTech SE | Ionizable thioplipids and uses thereof |
| WO2025027089A1 (en) | 2023-08-01 | 2025-02-06 | BioNTech SE | Ionizable thiolipids and uses thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL145221A0 (en) | 1999-03-09 | 2002-12-01 | Large Scale Biology Corp Unive | Multiple component rna vector system for expression of foreign sequences |
| ES2330202T5 (es) * | 2001-09-06 | 2014-01-20 | Alphavax, Inc. | Sistemas vectores basados en replicones de alfavirus |
| EP1608762B1 (en) * | 2003-03-20 | 2014-01-08 | Alphavax, Inc. | Improved alphavirus replicons and helper constructs |
| FR2862982B1 (fr) * | 2003-12-02 | 2006-04-28 | Genethon | Particules virales contenant un vecteur derive d'alpha-virus et procede de preparation de ladite particule virale. |
| WO2008119827A1 (en) * | 2007-04-02 | 2008-10-09 | Fit Biotech Oy | Transreplicase constructs |
| EP2167523B1 (en) | 2007-06-19 | 2014-07-23 | Board of Supervisors of Louisiana State University and Agricultural and Mechanical College | Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap |
| AU2008266807B2 (en) * | 2007-06-21 | 2012-08-16 | Alphavax, Inc. | Promoterless cassettes for expression of alphavirus structural proteins |
| BRPI0815576A2 (pt) | 2007-08-20 | 2015-02-18 | Glaxo Group Ltd | Método para produzir uma linha celular que produz uma proteína terapêutica, segunda linha celular transformada com uma segunda seqüência de polinucleotídeos, vetor, cassete de expressão amplificado, linha celular ou sua progênie, e, anticorpo. |
| PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
| DE102008061522A1 (de) | 2008-12-10 | 2010-06-17 | Biontech Ag | Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung |
| EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
| EP3449910A1 (en) | 2010-07-06 | 2019-03-06 | GlaxoSmithKline Biologicals S.A. | Cationic oil-in-water emulsions |
| BR112013000244A2 (pt) | 2010-07-06 | 2016-05-17 | Novartis Ag | lipossomas com lipídeos apresentando pka vantajoso para administração de rna |
| RU2577983C2 (ru) | 2010-08-31 | 2016-03-20 | Новартис Аг | Липиды, подходящие для липосомной доставки кодирующей белок рнк |
| SI2611461T1 (sl) | 2010-08-31 | 2022-08-31 | Glaxosmithkline Biologicals Sa | Pegilirani liposomi za dostavo imunogen-kodirajoče RNA |
| LT4043040T (lt) | 2010-08-31 | 2023-03-27 | Glaxosmithkline Biologicals Sa | Mažosios liposomos, skirtos imunogeną koduojančios rnr pristatymui |
| AU2011316707A1 (en) | 2010-10-11 | 2013-05-09 | Novartis Ag | Antigen delivery platforms |
| US9636410B2 (en) | 2011-07-06 | 2017-05-02 | Glaxosmithkline Biologicals Sa | Cationic oil-in-water emulsions |
| RU2606846C2 (ru) | 2011-07-06 | 2017-01-10 | Новартис Аг | Эмульсии типа "масло в воде", которые содержат нуклеиновые кислоты |
| WO2013006825A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Liposomes having useful n:p ratio for delivery of rna molecules |
| BR112014004607A2 (pt) | 2011-08-31 | 2017-03-21 | Novartis Ag | lipossomas peguilados para entrega de rna codificado imunogênico |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| US8961995B2 (en) * | 2012-09-20 | 2015-02-24 | Uab Research Foundation | Methods and compositions for alphavirus replicons |
| WO2014071963A1 (en) | 2012-11-09 | 2014-05-15 | Biontech Ag | Method for cellular rna expression |
| WO2016005004A1 (en) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
-
2016
- 2016-03-21 WO PCT/EP2016/056165 patent/WO2017162266A1/en active Application Filing
-
2017
- 2017-03-13 CA CA3017272A patent/CA3017272A1/en active Pending
- 2017-03-13 KR KR1020187027294A patent/KR102161607B1/ko active IP Right Grant
- 2017-03-13 AU AU2017236239A patent/AU2017236239B2/en active Active
- 2017-03-13 DK DK17710528.5T patent/DK3433369T3/da active
- 2017-03-13 SM SM20220047T patent/SMT202200047T1/it unknown
- 2017-03-13 LT LTEP20156693.2T patent/LT3701959T/lt unknown
- 2017-03-13 CN CN201780019155.1A patent/CN108884473B/zh active Active
- 2017-03-13 RS RS20220067A patent/RS62864B1/sr unknown
- 2017-03-13 PL PL17710528T patent/PL3433369T3/pl unknown
- 2017-03-13 CN CN202210935299.4A patent/CN115927467A/zh active Pending
- 2017-03-13 HR HRP20220044TT patent/HRP20220044T1/hr unknown
- 2017-03-13 MX MX2018011383A patent/MX2018011383A/es unknown
- 2017-03-13 SI SI201731043T patent/SI3701959T1/sl unknown
- 2017-03-13 SI SI201730212T patent/SI3433369T1/sl unknown
- 2017-03-13 PL PL20156693T patent/PL3701959T3/pl unknown
- 2017-03-13 US US16/086,157 patent/US11168337B2/en active Active
- 2017-03-13 SG SG11201807374WA patent/SG11201807374WA/en unknown
- 2017-03-13 ES ES17710528T patent/ES2784711T3/es active Active
- 2017-03-13 JP JP2018549313A patent/JP7121443B2/ja active Active
- 2017-03-13 PT PT201566932T patent/PT3701959T/pt unknown
- 2017-03-13 RU RU2018131966A patent/RU2748892C2/ru active
- 2017-03-13 EP EP20156693.2A patent/EP3701959B1/en active Active
- 2017-03-13 DK DK20156693.2T patent/DK3701959T3/da active
- 2017-03-13 PT PT177105285T patent/PT3433369T/pt unknown
- 2017-03-13 ES ES20156693T patent/ES2906807T3/es active Active
- 2017-03-13 HU HUE17710528A patent/HUE050350T2/hu unknown
- 2017-03-13 HU HUE20156693A patent/HUE059139T2/hu unknown
- 2017-03-13 WO PCT/EP2017/055808 patent/WO2017162460A1/en active Application Filing
- 2017-03-13 EP EP17710528.5A patent/EP3433369B1/en active Active
-
2018
- 2018-08-17 ZA ZA201805519A patent/ZA201805519B/en unknown
- 2018-08-26 IL IL261379A patent/IL261379B/en unknown
-
2019
- 2019-02-01 HK HK19101854.2A patent/HK1259449A1/zh unknown
-
2021
- 2021-10-05 US US17/494,601 patent/US20220033852A1/en active Pending
-
2022
- 2022-01-26 CY CY20221100063T patent/CY1125086T1/el unknown
- 2022-03-03 IL IL291100A patent/IL291100B2/en unknown
- 2022-08-02 JP JP2022123058A patent/JP7465310B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3433369T3 (da) | Rna-replikon til varieret og effektiv genekspression | |
| IL268788A (en) | Compositions and methods for enhanced gene expression | |
| DK3353299T3 (da) | Fremgangsmåder og stoffer til målrettet rna-editering | |
| DK3433368T3 (da) | Transreplikerende rna | |
| DK3325669T3 (da) | Sammensætninger og fremgangsmåder til RNA-analyse | |
| DK3390631T3 (da) | Fremgangsmåder og sammensætninger til t-rna-baseret guide-rna-ekspression | |
| IL269202A (en) | Methods and processes for assessment of genetic mosaicism | |
| HUE054159T2 (hu) | HPK1 gátlók és azok alkalmazási módja | |
| DK3280441T3 (da) | Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3299469T3 (da) | Systemer og fremgangsmåder til at stregkodemarkere nukleinsyre | |
| DK3108009T3 (da) | Fremgangsmåder og sammensætninger til DNA-profilering | |
| DK3548033T3 (da) | Forbindelser og deres fremgangsmåde til anvendelse | |
| DK3303386T3 (da) | Anti-Tau-antistoffer og fremgangsmåder til anvendlelse | |
| DK3183260T3 (da) | Modificerede oligonukleotider og fremgangsmåder til deres syntese | |
| DK3394065T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf | |
| DK3265043T3 (da) | Hjælpemiddel til patienttransport og -træning | |
| DK3319611T3 (da) | Oxysteroler og fremgangsmåder til anvendelse deraf | |
| DK3319612T3 (da) | Oxysteroler og fremgansmåder til anvendelse derfor | |
| DK3368655T3 (da) | Forbedret proteinekspression og fremgangsmåder dertil | |
| DK3177608T3 (da) | Proteinkinase-C-hæmmere og fremgangsmåder til anvendelse deraf | |
| DK3234160T3 (da) | Sammensætninger og fremgangsmåder til hjælper-stamme-medieret svampegenommodifikation | |
| DK3353168T3 (da) | Forbindelser og fremgangsmåder til at inhibere jak | |
| DK3167076T3 (da) | Fremgangsmåder og produkter til kvantificering af RNA-transkriptvarianter | |
| DK3100050T3 (da) | Immobiliserede proteiner og anvendelse deraf | |
| DK3420039T3 (da) | Printningsformuleringer og fremgangsmåder |